Comments for Takeover Targets: After Medarex, investors ask who's next at http://www.biomedreports.com , comment 1 to 1 out of 1 comments http://www.biomedreports.com Wed, 08 Feb 2012 03:25:29 +0100 FeedCreator 1.7.3 http://www.biomedreports.com/200907232396/takeover-targets-after-medarex-investors-ask-whos-next.html#comment-539 Medarex shareholders have taken extrordinary risks over the years with this company. Now that Medarex is about to capitalize on its pipeline, BMS is offering medarex shareholders a fraction of what this company is truly worth The fact that Medarex management negotiated and accepted an offer of $16.00 dollars per-share is an outrage. Considering the long-term benefits to BMS and the fact that Ulti-mab antibody platform is the Gold Standard in human antibody technology, it is clear to me that Medarex Management should have attempted to obtain a better price for their shareholders. Depending on many factor BMS stands to make between 6 and 10 billion dollars and possibly more over the next decade, as antibodies generated by medarex technology achieve market status. The fact that Mr. Pien, current Medarex CEO isgoing to be paid a muti-million dollar bonus is very disconcerting outrage as well.Medarex shareholders can do better than this - James Castle Sat, 25 Jul 2009 03:56:15 +0100